(Total Views: 464)
Posted On: 07/24/2019 9:23:10 AM
Post# of 72433
"Major international pharma, Alfasigma licensed Brilacidin as a new drug for IBDs ulcerative proctitis and ulcerative proctosigmoiditis from Innovation Pharma for $24 million cash and 6% royalties."
So SA sees $24m total cash also.
So SA sees $24m total cash also.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
Leo Took The Money and Ran